搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
ophthalmologytimes
11 小时
Managing mental health in glaucoma
A large number of studies have focused on mental health declines associated with glaucoma. For example, about one-third of ...
ophthalmologytimes
1 天
Mount Sinai gifted $5 million for the center for ophthalmic artificial intelligence and ...
The Center, which was launched in 2023, will now be named The Barry Family Center for Ophthalmic Artificial Intelligence and ...
ophthalmologytimes
1 天
The impact of cross-linking on corneal transplant rates
Corneal cross-linking has led to a significant decline in corneal transplant rates for keratoconus globally. Cross-linking ...
ophthalmologytimes
2 天
German Ophthalmological Society awards Theodor Leber Medal and honorary society memberships
The DOG recognised Heidelberg Engineering founder Christoph Schoess, Prof Herbert Kaufmann, and Prof Ioannis G. Pallikaris ...
ophthalmologytimes
2 天
AAO 2024: Centricity Vision to unveil new ZEPTOLink enhancements for improved efficiency ...
Centricity Vision announced new ZEPTOLink enhancements, reducing treatment time by up to 60%. These updates, aimed at ...
ophthalmologytimes
2 天
Oculis to present phase 3 DIAMOND program updates at Innovate Retina and Eyecelerator 2024
David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from ...
ophthalmologytimes
2 天
Unlocking health mysteries
AD is a neurodegenerative disease characterized by neuronal loss in the cerebral cortex and the formation of extracellular ...
ophthalmologytimes
3 天
Anthony Wallace of Bausch + Lomb talks about enVista Envy FDA approval
The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.
ophthalmologytimes
3 天
FDA approves Bausch + Lomb’s enVista Envy range of IOLs
According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...
ophthalmologytimes
5 天
Paper: Rising diabetic retinopathy rates in youth signal potential public health crisis
A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over ...
ophthalmologytimes
5 天
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II ...
The DRAGON II trial evaluates Tinlarebant's efficacy, safety, and tolerability in adolescent STGD1 subjects across the US, UK, and Japan. The trial's initiation in Japan provides unprecedented access ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈